Subject dosing is complete in a phase 1/2 clinical trial of an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.
AURN001 (Aurion Biotech) is a combination cell therapy made from neltependocel, or allogeneic human corneal endothelial cells, and Y-27632, an inhibitor of Rho-associated coiled-coil containing protein kinase. It is administered as a one-time intracameral injection.
In the CLARA trial, three different doses of neltependocel used in combination with Y-27632 are being evaluated in 97 subjects. The